Stereotactic Body Radiotherapy: An Emerging Treatment Approach for Localized Prostate Cancer

Open Access Article

The authors, the publisher, and the right holders grant the right to use, reproduce, and disseminate the work in digital form to all users.

Technology in Cancer Research and TreatmentISSN 1533-0346Volume 8, Number 5, October 2009©Adenine Press (2009)

Jay L. Friedland, M.D.1Debra E. Freeman, M.D.1* Mary Ellen Masterson- McGary, M.A., M.S.2David M. Spellberg, M.D.3

1Naples Radiation Oncology, PA 2 Cyberknife Centers of Tampa Bay3Naples Urology Associates, PA

Stereotactic Body Radiotherapy: An Emerging Treatment Approach for Localized Prostate Cancer

Link to full article: http://www.tcrt.org/index.cfm?d=3036&c=4295&p=17748&do=detail

Here we report results from the first cohort of over 100 patients treated with hypofractionated, stereotactic body radiotherapy (SBRT) for early stage prostate cancer. Between February 2005 and December 2006, 112 patients with localized, biopsy-proven adenocarcinoma of the prostate (clinical stage T1cN0M0 to T2cN0M0) were treated in Naples, FL on a CyberKnife system (Accuray Incorporated, Sunnyvale, CA). Eighty-one patients had a Gleason score of 3+3. Mean initial PSA was 6.0, and mean initial prostate volume was 46.3cc. Implanted gold fiducials were used for image-guided targeting and tracking. Patients received 35-36 Gy administered in 5 consecutive fractions to the prostate and the proximal seminal vesicles, as identified on CT and MRI scans. At a median follow-up of 24 months, the mean PSA value was 0.78 ng/ml. Two patients have developed biopsy-confirmed local relapse; one developed distant metastases. Acute side effects were generally mild and resolved shortly after treatment. A single Grade 3 rectal complication was reported (bleeding). Eighty-two percent of patients who were sexually potent before treatment maintained erectile function post-treatment. Additional follow-up is required to better evaluate potential late toxicity and long-term PSA outcomes.